<DOC>
	<DOCNO>NCT02547675</DOCNO>
	<brief_summary>To provide access rociletinib patient advance metastatic EGFR-mutant NSCLC treat previously EGFR direct therapy evidence T790M mutation ( T790M+ ) .</brief_summary>
	<brief_title>Rociletinib ( CO-1686 ) USA Expanded Access Program</brief_title>
	<detailed_description>This open-label , multi-center study US , allow expanded access rociletinib patient advance metastatic , EGFR-mutant T790M+ NSCLC previously treat least one prior EGFR TKI therapy ( â‰¥2nd line ) . Patients receive oral rociletinib twice daily study long clinical benefit access FDA-approved rociletinib .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Key Unresectable locally advance metastatic NSCLC EGFR activate mutation ( exclude exon 20 insertion ) presence T790M mutation Prior treatment approve experimental EGFRdirected therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Adequate hematological biological function Written inform consent Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) approve ICF studyspecific evaluation Key Eligibility enrol clinical trial rociletinib Leptomeningeal carcinomatosis untreated symptomatic CNS metastasis ( asymptomatic CNS metastasis allow clinically stable without requirement steroid dose increase least 4 week ) History prior interstitial lung disease Concurrent use QTprolonging medication Cardiac abnormality : Clinically significant abnormal 12lead ECG , QT interval correct use Fridericia 's method ( QTcF ) &gt; 450 m Inability measure QT interval ECG Personal family history long QT syndrome Implantable pacemaker implantable cardioverter defibrillator Resting bradycardia &lt; 55 beats/min Presence serious unstable concomitant systemic disorder incompatible clinical study ( eg , substance abuse , uncontrolled intercurrent illness include active infection , arterial thrombosis , symptomatic pulmonary embolism , active malignancy associate life expectancy le 1 year ) Pregnant breastfeed female male female patient refuse use adequate contraception study 12 week last dose rociletinib Any contraindication , allergy , hypersensitivity rociletinib excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>